CN1682896A - Medicine for treating infantile inflammation of upper respiratory tract and its preparing method - Google Patents
Medicine for treating infantile inflammation of upper respiratory tract and its preparing method Download PDFInfo
- Publication number
- CN1682896A CN1682896A CN 200510041787 CN200510041787A CN1682896A CN 1682896 A CN1682896 A CN 1682896A CN 200510041787 CN200510041787 CN 200510041787 CN 200510041787 A CN200510041787 A CN 200510041787A CN 1682896 A CN1682896 A CN 1682896A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- standby
- medicine
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of medicine for treating infantile inflammation of upper respiratory tract and its preparation process. The medicine is prepared with artificial bezoar, earthworm, bistort rhizome, pearl ox bile powder, licorice and other 11 kinds of Chinese medicinal materials. The medicine has the functions of clearing away heat and toxic material, eliminating phlegm, relieving cough, relieving stasis and arresting convulsion, and is suitable for use in treating infantile retention of phlegm-heat in the lung to cause fever, cough, asthma and other symptoms. It has high curative effect and no obvious bad reaction.
Description
One, technical field:
The present invention relates to a kind of medicine for the treatment of infantile inflammation of upper respiratory tract and preparation method thereof.
Two, technical background:
Infantile inflammation of upper respiratory tract is a usual diseases of childhood, and one of frequently-occurring disease is a cardinal symptom with heating, aphtha of the mouth and tongue, throat or almond bodily pain, nasal obstruction watery nasal discharge etc.; Sometimes course of disease delay, pulmonary's sign disappears slowly, and expectorant is difficult for expectoration, and the satisfaction that the is applicable to children's at present medicine that effectively reduces phlegm is still rare.
Three, summary of the invention:
The object of the present invention is to provide the effect that a kind ofly has heat-clearing and toxic substances removing, preventing phlegm from forming and stopping coughing, has one's ideas straightened out arresting convulsion, be applicable to the very then medicine and preparation method thereof of the treatment infantile inflammation of upper respiratory tract of disease such as tic of hyperpyrexia that children's's heat-phlegm and blocking lung causes, coughing and wheezing, abundant expectoration.
For achieving the above object, the technical solution used in the present invention is:
A kind of medicine for the treatment of infantile inflammation of upper respiratory tract, its special character are that it is a medicament by the following weight proportion raw material:
Artificial Calculus Bovis 26.4-39.6 part Pheretima 440-660 part Margarita 26.4-39.6 part
Rhizoma Bistortae 352-528 part bilein 88-132 part Radix Glycyrrhizae 88-132 part
Bulbus Fritillariae Ussuriensis 528-792 part Moschus 1.76-2.64 part Rhizoma Belamcandae 440-660 part
Cinnabaris 3.52-5.28 part Rhizoma Coptidis 352-528 part Radix Scutellariae 704-1056 part
Cornu Saigae Tataricae 3.52-5.28 part Mirabilitum crystallina 440-660 part Borneolum Syntheticum 3.52-5.28 part
Radix Arnebiae (Radix Lithospermi) 264-396 part Radix Bupleuri 528-792 part
The medicine of above-mentioned treatment infantile inflammation of upper respiratory tract, wherein the weight proportion of each raw material is:
Artificial Calculus Bovis 29.7-36.3 part Pheretima 495-605 part Margarita 29.7-36.3 part
Rhizoma Bistortae 396-484 part bilein 99-121 part Radix Glycyrrhizae 99-121 part
Bulbus Fritillariae Ussuriensis 594-726 part Moschus 1.98-2.42 part Rhizoma Belamcandae 495-605 part
Cinnabaris 3.96-4.84 part Rhizoma Coptidis 396-484 part Radix Scutellariae 792-968 part
Cornu Saigae Tataricae 3.96-4.84 part Mirabilitum crystallina 495-605 part Borneolum Syntheticum 3.96-4.84 part
Radix Arnebiae (Radix Lithospermi) 297-363 part Radix Bupleuri 594-726 part
The medicine of above-mentioned treatment infantile inflammation of upper respiratory tract, wherein the weight proportion of each raw material is:
33 parts of 550 parts of Margaritas of 33 parts of Pheretimas of artificial Calculus Bovis
110 parts in 110 portions of Radix Glycyrrhizaes of 440 parts of bileins of Rhizoma Bistortae
550 parts of 2.2 parts of Rhizoma Belamcandae of 660 parts of Moschus of Bulbus Fritillariae Ussuriensis
880 parts of 440 parts of Radix Scutellariaes of 4.4 portions of Rhizoma Coptidis of Cinnabaris
4.4 parts of 550 parts of Borneolum Syntheticums of 4.4 parts of Mirabilitum crystallinas of Cornu Saigae Tataricae
660 parts of 330 parts of Radix Bupleuri of Radix Arnebiae (Radix Lithospermi)
Above-mentioned medicament is the above dosage form of saying of any pharmaceutics.
Above-mentioned medicament is capsule, tablet.
Above-mentioned dosage form is that the processing step of capsular preparation method is as follows:
(1), Rhizoma Coptidis, Bulbus Fritillariae Ussuriensis, Mirabilitum crystallina are ground into fine powder, standby;
(2), Rhizoma Belamcandae, Rhizoma Bistortae, Radix Arnebiae (Radix Lithospermi), Radix Scutellariae, Pheretima, Radix Bupleuri, Radix Glycyrrhizae added 10 times of water gagings decoct secondaries, 2 hours for the first time, 1 hour for the second time, collecting decoction filtered, it is 1.23-1.26 that filtrate is concentrated into relative density, the clear paste when temperature is 75 ℃ is standby;
(3), Cinnabaris, Margarita water are flown or be ground into fine powder, standby;
(4), Cornu Saigae Tataricae file is ground into fine powder, standby;
(5), with artificial Calculus Bovis, Moschus porphyrize respectively, standby;
(6), with the fine powder of step (3), (4), (5) preparation and the fine powder of step (1) preparation, the clear paste of step (2) preparation, bilein and an amount of lactose mixing are granulated, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, granulation incapsulates, promptly.
Above-mentioned dosage form is that the processing step of preparation method of tablet is as follows:
(1), Rhizoma Coptidis, Bulbus Fritillariae Ussuriensis, Mirabilitum crystallina are ground into fine powder, standby;
(2), Rhizoma Belamcandae, Rhizoma Bistortae, Radix Arnebiae (Radix Lithospermi), Radix Scutellariae, Pheretima, Radix Bupleuri, Radix Glycyrrhizae added 10 times of water gagings decoct secondaries, 2 hours for the first time, 1 hour for the second time, collecting decoction filtered, it is 1.23-1.26 that filtrate is concentrated into relative density, the clear paste when temperature is 75 ℃ is standby;
(3), Cinnabaris, Margarita water are flown or be ground into fine powder, standby;
(4), Cornu Saigae Tataricae file is ground into fine powder, standby;
(5), with artificial Calculus Bovis, Moschus porphyrize respectively, standby;
(6), with the fine powder of step (3), (4), (5) preparation and the fine powder of step (1) preparation, the clear paste of step (2) preparation, bilein and an amount of lactose mixing are granulated, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, compacting is wrapped film-coat, promptly in flakes.
The present invention is with respect to prior art, and its advantage is as follows:
It is definite that the present invention applies to clinical efficacy, have heat-clearing and toxic substances removing, preventing phlegm from forming and stopping coughing, the effect of the arresting convulsion of having one's ideas straightened out, be applicable to very then disease such as tic of hyperpyrexia that children's's heat-phlegm and blocking lung causes, coughing and wheezing, abundant expectoration, clinical research confirmation, truly have good effect, and do not see that obvious adverse reaction is arranged.
Four, the specific embodiment:
The present invention is made of artificial Calculus Bovis, Pheretima, Margarita, Rhizoma Bistortae, bilein, Radix Glycyrrhizae, Bulbus Fritillariae Ussuriensis, Moschus, Rhizoma Belamcandae, Cinnabaris, Rhizoma Coptidis, Radix Scutellariae, Cornu Saigae Tataricae, Mirabilitum crystallina, Borneolum Syntheticum, Radix Arnebiae (Radix Lithospermi), Radix Bupleuri; its medication is precise and appropriate; compatibility is reasonable; all medicines share; have heat-clearing and toxic substances removing, preventing phlegm from forming and stopping coughing, the effect of the arresting convulsion of having one's ideas straightened out, be applicable to very then disease such as tic of hyperpyrexia that children's's heat-phlegm and blocking lung causes, coughing and wheezing, abundant expectoration, clinical research confirmation; truly have good effect, and do not see that obvious adverse reaction is arranged.
For verifying its curative effect, now the clinical observation on the therapeutic effect result is reported as follows:
1. infantile pneumonia
Infantile pneumonia is the clinical common frdquently encountered disease of department of pediatrics, course of disease delay sometimes, and pulmonary's sign disappears slowly, and expectorant is difficult for expectoration.The satisfaction that the is applicable to children's at present medicine that effectively reduces phlegm is still rare, controls infantile pneumonia and carries out clinical observation on the therapeutic effect, existing the result is reported as follows: data and method
1, case is selected and grouping: prevent and treat the scheme diagnostic criteria by infantile pneumonia in 1987, select 120 routine infants in my institute's Pediatric Clinic and inpatient.Wherein male 78 examples, women 42 examples, June at age～12 years old.The onset time is all in a week.All because of heating, cough, tachypnea is gone to a doctor or is admitted to hospital.Equal audible of two lungs and fixing dried, moist rale, rabat shows increased bronchovascular shadows, visible mottling.120 routine infants were divided into 2 groups by 2: 1 at random, and 80 examples are organized in treatment, used the present invention.Matched group 40 examples are used brown mixture.Onset time and symptom before two groups of treatments, sign are similar substantially.
2, observation item: all make rabat X ray examination before the treatment, treatment beginning is write down body temperature, pulsation, breathing, coughs, coughs up phlegm every day, thick sputum degree, amount of expectoration, pulmonary are done, moist rale and toxicity.
3, method: all prevent and treat standard for two groups by pneumonia, the conventional use under the antibiotic prerequisite, the treatment group adds uses the present invention, June～1 years old; 1/2,3 times on the one; 2～3 years old, 1,3 times on the one; 4～7 years old, 1/1/2,3 times on the one; 8～12 years old, 2,3 times on the one.Matched group adds uses brown mixture, routine dose 1ml/ year time, 3 times on the one.
4, curative effect is judged: behind the treatment 5d, produce effects: tachypnea, cough, cough up phlegm obviously alleviate, the thick sputum degree changes rare, amount reduces, pulmonary rale obviously reduces.Effectively: tachypnea, cough, coughing up phlegm alleviates, sputum is by R-L, measures morely, pulmonary rale reduces.Invalid: tachypnea, cough, cough up phlegm and pulmonary's sign, thick sputum degree, amount do not have and change.
The result
1, pulmonary's sign is improved situation: 80 routine children pneumonia are controlled with matched group through the present invention's assistant and are compared, cough, and tachypnea is clearly better, and it is fast than matched group that pulmonary does, moist rale disappears, and it is rare that sputum changes, easily expectoration, it is few that amount is changeed.Treatment group obvious effective rate (38/80 example) 47.5%, effective percentage (30/80 example) 37.5%, inefficiency (12/80 example) 15%, total effective rate 85%.And matched group obvious effective rate (8/40 example) 20%, effective percentage (18/40 example) 45%, inefficiency (14/40 example) 35%, total effective rate 65% (P＜0.01), there were significant differences.
2, length of stay: average 8.4 ± 1.4d is organized in treatment, the average 10.4 ± 1.6d of matched group, two groups of significant differences, t=3.14 (P＜0.01).
3, side effect: the treatment group has 4 routine baby's times of defecation to increase after using the present invention, and 4～5 times/d, symptom promptly disappears after the drug withdrawal, and all the other do not have other untoward reaction.
2. hyperpyrexia convulsion
Hyperpyrexia convulsion (being called for short FC) is the department of pediatrics emergency case, sickness rate is 2%～3% in children's below 5 years old, in febrile disease body temperature rise process, more easily take place, generally do not stay sequela, but the persistent period of fainting from fear is long, or takes place repeatedly, can cause brain tissue injury, and the minority case repeatedly recurs and can transfer epilepsy to, leaves over delayed ischemic neurological deficits such as mental retardation and dystropy, so can not regard as unimportant.Therefore, it is necessary prophylactic treatment being carried out in the hyperpyrexia convulsion recurrence.Use the present invention in December, 1998～2003 year JIUYUE and prevent the hyperpyrexia convulsion recurrence, obtain comparatively satisfied curative effect, now report as follows:
1 clinical data
Case is selected to meet the whole nation, nineteen eighty-three Zi Gong child neurosis and is learned the children's typical case hyperpyrexia convulsion diagnostic criteria that symposium is formulated, and show effect outpatient service that (contains 2 times) more than 2 times and the FC infant of being in hospital 63 examples are divided into 2 groups at random for the object of observation, and 32 examples are organized in treatment, man's 19 examples, women 13 examples; 13 months～3.5 years old age, average (2.01 ± 0.52) year.Matched group 31 examples, male 18 examples, women 13 examples; 16 months～3.4 years old age, average (2.08 ± 0.72) year.The difference equal not statistically significant of two groups of infants aspect sex, age, heating, body temperature, convulsive seizure number of times and family members' history has comparability.
2 Therapeutic Method
It is oral that the treatment group infant initial stage of at every turn generating heat is promptly given the present invention, dosage be 1 years old with interior each 0.15g, 1～3 years old each 0.3g, each 0.6g more than 3 years old, per 8 hours are once, obey altogether 2 days.The each heating of matched group infant promptly gives oral phenobarbital+aspirin, each per kilogram of body weight 1mg, and per 8 hours are once, obey altogether 2 days.All observed continuously 1 year for two groups, all treat protopathy and anti symptom treatment for two groups simultaneously.Energy swallowable capsule, tablet person directly take with warm water.
3 observation of curative effect
3.1 observational technique in to every routine infant therapeutic process, write down at any time infant body temperature, heating number of times, generate heat and the number of times that falls into convulsions and change of illness state, the medicine toxicity of appearance.Statistical analysis adopts SPSS software to carry out, and enumeration data adopts χ
2The t check is adopted in check, measurement data.
3.2 32 examples are organized in the therapeutic outcome treatment, hyperpyrexia convulsion occurs and recur 3 examples, relapse rate is 9.38%, and the heating total degree is 94 times; Matched group 31 examples hyperpyrexia convulsion occurs and recur 2 examples, and relapse rate is 6.45%, and the heating total degree is 151 times; At convulsions relapse rate two group difference not statistically significants, χ
2=0.1575, P=0.6918; Heating total degree two group differences have statistical significance, χ
2=3.8970, P=0.0484.
3.3 the appearance stool was half congealed partially after the untoward reaction treatment was organized 7 routine infant clothes the present invention are arranged in 32 examples, drowsiness situation appears after having 10 routine infants to take phenobarbital in matched group 31 examples, all do not do special handling for two groups, all recover normal after the drug withdrawal, the surplus obvious adverse reaction that do not occur.
3. infantile inflammation of upper respiratory tract
Infantile inflammation of upper respiratory tract is a usual diseases of childhood, and one of frequently-occurring disease is a cardinal symptom with heating, aphtha of the mouth and tongue, throat or almond bodily pain, nasal obstruction watery nasal discharge etc.The present invention has heat clearing away, relieving convulsion, Detoxication.My institute uses the present invention from July, 98 to August and treats infantile inflammation of upper respiratory tract 30 examples, and carries out controlled observation with GUASHUANG TUIRE LING 10 examples, now the result is reported as follows.
1 physical data
Treatment group and matched group are pressed random assortment in 3: 1, treatment group the present invention's 30 examples, matched group GUASHUANG TUIRE LING 10 examples.Male 16 examples are organized in treatment, women 14 examples, wherein＜and 2 years old 4 example, 2--7 year 22 examples,＞7 years old 4 example.Matched group man 7 examples, women 3 examples,＜2 years old 3 example, 2--7 year 6 examples,＞7 years old 1 example.
2. diagnostic criteria
2.1 essential condition throat or tonsil swell and ache.
2.2 1. other conditions generate heat (anus thermometre is more than 37.5 ℃); 2. aphtha of the mouth and tongue, tooth are envious swollen; 3. the watery nasal discharge of having a stuffy nose; 4. cigarette is hot-tempered easily frightened, sleep disorder; 5. appetite stimulator, halitosis, abdominal distention.
But all possess above essential condition and have person person of other conditions concurrently.
All case courses of disease are in 3 days.
3. administrated method
Treatment group 0.3g of the present invention, 2 times on the 1st, 0.15g below 3 years old, 2 times on the 1st.Matched group GUASHUANG TUIRE LING 0.6g, 2 times on the 1st, 0.3g below 3 years old, 2 times on the 1st.3 days courses of treatment.
4. criterion of therapeutical effect
1. recovery from illness: take medicine clinical symptoms in 24-120 hour, sign complete obiteration, index recover normal.
2. produce effects: take medicine clinical symptoms in 24-120 hour, sign are near normal, and integration descends) 2/30
3. effective: the clinical symptoms in 24-120 hour of taking medicine, sign indexing section disappear, and integration descends) 1/20
4. invalid: as not reach above standard person.
Attached standards of grading: symptom, sign grade be by increasing the weight of to be divided into " 0 " gradually, totally 4 grades of "+", " ++ ", " +++", be chosen as respectively " 0 minute ", " 1 minute ", " 2 minutes ", " 3 minutes ".Pharyngitis or the tonsil person of swelling and ache add 2 fens on the original basis; The heating anus thermometre adds 1 fen person more than 38.5 ℃.
5. result
Treatment group and matched group obvious effective rate (comprising cure rate) are respectively 70% and 50%; Total effective rate is respectively 90% and 80%.
6. side effect
Two groups in the medication process, diarrhoea 3 examples take place in the treatment group, 1 example takes place in matched group, all transference cure after the drug withdrawal.
4. infantile lung heat cough
We treat infantile lung heat 148 examples of coughing from utilization in August, 2000 from the present invention, and establish matched group 52 examples and observe, and now report as follows:
1 physical data
200 routine patients all are the outpatient. be divided into treatment group and matched group at random.148 examples are organized in treatment. wherein male 94 examples, women 54 examples; Maximum 14 years old, minimum June; 0-3 year 52 examples, 4-7 year 78 examples, 18 examples more than 8 years old; The course of disease 7 days is with interior 76 examples, 7-15 days 22 examples, 15-30 days 28 examples, 21 examples more than 30 days; Hot person's 22 examples occur together. abundant expectoration person 46 examples, asthma person's 14 examples; There are sign person's 41 examples in pulmonary, looks into mycoplasma pneumoniae positive person 23 examples.Matched group 52 examples, wherein male 28 examples, women 24 examples, maximum 14 years old, minimum May, 0-3 year 28 examples, 4-7 year 15 examples, 9 examples more than 8 years old; The course of disease 7 days is with interior 36 examples, 7-15 days 12 examples, 4 examples more than 30 days; Hot person's 25 examples that occur together, abundant expectoration person 21 examples, asthma person's 7 examples; There are sign person's 21 examples in pulmonary, looks into mycoplasma pneumoniae positive person s example.Basic condition there was no significant differences such as two groups of ages, sex, the course of disease have comparability.
Diagnostic criteria reference State Administration of Traditional Chinese Medicine's formulation in 1988 (diagnostic criteria of TCM Pediatrics disease ".All infants all have cough, red tongue, white and thin fur or little Huang, floating and rapid pulse, fingerprint purple.Be secondary to after the flu more, often because of climate change shows effect, the infant of abundant expectoration, audible rale sound between larynx, good being sent out in winter, two seasons of spring.
2. Therapeutic Method
The present invention of treatment group, oral, once obeyed 0.125g with interior children's in six months; Once obeyed 0.25g in seven to 12 months; One-year-oldly once obeyed 0.375g to two years old; Once obeyed 0.5g in two years old to three years old; Three years old with last time clothes 0.75～1.0g, 3～4 times on the one.
Matched group is used: penicillin: 200,000 u/kg/ days, 1 time/day dead point, or clindamycin: 15-25mg/kg//day, 1 time/day dead point; If any heating, diarrhoea, constipation etc., can be according to state of an illness symptomatic treatment.
Two groups of cases were a course of treatment with 3 days all, continuous two courses of treatment, judged curative effect.
3. criterion of therapeutical effect
Recovery from illness: the last of the twelve Earthly Branches disappearance of coughing, no expectorant sound between larynx, body temperature is reduced to normally if any generating heat then.Take a turn for the better: cough alleviates, and expectorant reduces.Invalid: the cough symptom is not seen improvement or is increased the weight of.
4. therapeutic outcome
Curative effect sees Table 1.Clinical efficacy relatively has significance (P＜0.01) for two groups.
Table 1 liang group clinical efficacy comparative example (%)
| Group | The example number | Recovery from illness | Take a turn for the better | Invalid | Total effective rate |
| Treatment group matched group | ??148 ??52 | ??107(72.3) ??27(51.9) | ??35(23.6) ??15(28.8) | ??6(4.1) ??10(19.3) | ??(96) ??(80.7) |
Embodiment 1:
Take by weighing raw material by following proportioning:
Artificial Calculus Bovis 33g Pheretima 550g Margarita 33g
Rhizoma Bistortae 440g bilein 110g Radix Glycyrrhizae 110g
Bulbus Fritillariae Ussuriensis 660g Moschus 2.2g Rhizoma Belamcandae 550g
Cinnabaris 4.4g Rhizoma Coptidis 440g Radix Scutellariae 880g
Cornu Saigae Tataricae 4.4g Mirabilitum crystallina 550g Borneolum Syntheticum 4.4g
Radix Arnebiae (Radix Lithospermi) 330g Radix Bupleuri 660g
Its processing step that is made as capsular preparation method is as follows:
(1), Rhizoma Coptidis, Bulbus Fritillariae Ussuriensis, Mirabilitum crystallina are ground into fine powder, standby;
(2), Rhizoma Belamcandae, Rhizoma Bistortae, Radix Arnebiae (Radix Lithospermi), Radix Scutellariae, Pheretima, Radix Bupleuri, Radix Glycyrrhizae added 10 times of water gagings decoct secondaries, 2 hours for the first time, 1 hour for the second time, collecting decoction filtered, it is 1.23-1.26 that filtrate is concentrated into relative density, the clear paste when temperature is 75 ℃ is standby;
(3), Cinnabaris, Margarita water are flown or be ground into fine powder, standby;
(4), Cornu Saigae Tataricae file is ground into fine powder, standby;
(5), with artificial Calculus Bovis, Moschus porphyrize respectively, standby;
(6), with the fine powder of step (3), (4), (5) preparation and the fine powder of step (1) preparation, the clear paste of step (2) preparation, bilein and an amount of lactose mixing are granulated, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, granulation incapsulates, promptly.
Embodiment 2:
Take by weighing raw material by following proportioning:
Artificial Calculus Bovis 26.4g Pheretima 440g Margarita 26.4g
Rhizoma Bistortae 352g bilein 88g Radix Glycyrrhizae 88g
Bulbus Fritillariae Ussuriensis 528g Moschus 1.76g Rhizoma Belamcandae 440g
Cinnabaris 3.52g Rhizoma Coptidis 352g Radix Scutellariae 704g
Cornu Saigae Tataricae 3.52g Mirabilitum crystallina 440g Borneolum Syntheticum 3.52g
Radix Arnebiae (Radix Lithospermi) 264g Radix Bupleuri 528g
Its processing step of preparation method that is made as tablet is as follows:
(1), Rhizoma Coptidis, Bulbus Fritillariae Ussuriensis, Mirabilitum crystallina are ground into fine powder, standby;
(2), Rhizoma Belamcandae, Rhizoma Bistortae, Radix Arnebiae (Radix Lithospermi), Radix Scutellariae, Pheretima, Radix Bupleuri, Radix Glycyrrhizae added 10 times of water gagings decoct secondaries, 2 hours for the first time, 1 hour for the second time, collecting decoction filtered, it is 1.23-1.26 that filtrate is concentrated into relative density, the clear paste when temperature is 75 ℃ is standby;
(3), Cinnabaris, Margarita water are flown or be ground into fine powder, standby;
(4), Cornu Saigae Tataricae file is ground into fine powder, standby;
(5), with artificial Calculus Bovis, Moschus porphyrize respectively, standby;
(6), with the fine powder of step (3), (4), (5) preparation and the fine powder of step (1) preparation, the clear paste of step (2) preparation, bilein and an amount of lactose mixing are granulated, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, compacting is wrapped film-coat, promptly in flakes.
Embodiment 3:
Take by weighing raw material by following proportioning:
39.6 parts of 660 parts of Margaritas of 39.6 parts of Pheretimas of artificial Calculus Bovis
132 parts in 132 portions of Radix Glycyrrhizaes of 528 parts of bileins of Rhizoma Bistortae
660 parts of 2.64 parts of Rhizoma Belamcandae of 792 parts of Moschus of Bulbus Fritillariae Ussuriensis
1056 parts of 528 parts of Radix Scutellariaes of 5.28 portions of Rhizoma Coptidis of Cinnabaris
5.28 parts of 660 parts of Borneolum Syntheticums of 5.28 parts of Mirabilitum crystallinas of Cornu Saigae Tataricae
792 parts of 396 parts of Radix Bupleuri of Radix Arnebiae (Radix Lithospermi)
Preparation technology is identical with embodiment 1; Certainly, the present invention also can be prepared into the above dosage form of saying of any pharmaceutics, as granule etc.
Claims (7)
1, a kind of medicine for the treatment of infantile inflammation of upper respiratory tract is characterized in that it is a medicament by the following weight proportion raw material:
Artificial Calculus Bovis 26.4-39.6 part Pheretima 440-660 part Margarita 26.4-39.6 part
Rhizoma Bistortae 352-528 part bilein 88-132 part Radix Glycyrrhizae 88-132 part
Bulbus Fritillariae Ussuriensis 528-792 part Moschus 1.76-2.64 part Rhizoma Belamcandae 440-660 part
Cinnabaris 3.52-5.28 part Rhizoma Coptidis 352-528 part Radix Scutellariae 704-1056 part
Cornu Saigae Tataricae 3.52-5.28 part Mirabilitum crystallina 440-660 part Borneolum Syntheticum 3.52-5.28 part
Radix Arnebiae (Radix Lithospermi) 264-396 part Radix Bupleuri 528-792 part
2, the medicine of treatment infantile inflammation of upper respiratory tract according to claim 1 is characterized in that: wherein the weight proportion of each raw material is:
Artificial Calculus Bovis 29.7-36.3 part Pheretima 495-605 part Margarita 29.7-36.3 part
Rhizoma Bistortae 396-484 part bilein 99-121 part Radix Glycyrrhizae 99-121 part
Bulbus Fritillariae Ussuriensis 594-726 part Moschus 1.98-2.42 part Rhizoma Belamcandae 495-605 part
Cinnabaris 3.96-4.84 part Rhizoma Coptidis 396-484 part Radix Scutellariae 792-968 part
Cornu Saigae Tataricae 3.96-4.84 part Mirabilitum crystallina 495-605 part Borneolum Syntheticum 3.96-4.84 part
Radix Arnebiae (Radix Lithospermi) 297-363 part Radix Bupleuri 594-726 part
3, the medicine of treatment infantile inflammation of upper respiratory tract according to claim 1 is characterized in that: wherein the weight proportion of each raw material is:
33 parts of 550 parts of Margaritas of 33 parts of Pheretimas of artificial Calculus Bovis
110 parts in 110 portions of Radix Glycyrrhizaes of 440 parts of bileins of Rhizoma Bistortae
550 parts of 2.2 parts of Rhizoma Belamcandae of 660 parts of Moschus of Bulbus Fritillariae Ussuriensis
880 parts of 440 parts of Radix Scutellariaes of 4.4 portions of Rhizoma Coptidis of Cinnabaris
4.4 parts of 550 parts of Borneolum Syntheticums of 4.4 parts of Mirabilitum crystallinas of Cornu Saigae Tataricae
660 parts of 330 parts of Radix Bupleuri of Radix Arnebiae (Radix Lithospermi)
4, according to the medicine of claim 1 or 2 or 3 described treatment infantile inflammation of upper respiratory tract, it is characterized in that: described medicament is the above dosage form of saying of any pharmaceutics.
5, the medicine of treatment infantile inflammation of upper respiratory tract according to claim 4 is characterized in that: described medicament is capsule, tablet.
6, the medicine of treatment infantile inflammation of upper respiratory tract according to claim 5 is characterized in that:
Described dosage form is that the processing step of capsular preparation method is as follows:
(1), Rhizoma Coptidis, Bulbus Fritillariae Ussuriensis, Mirabilitum crystallina are ground into fine powder, standby;
(2), Rhizoma Belamcandae, Rhizoma Bistortae, Radix Arnebiae (Radix Lithospermi), Radix Scutellariae, Pheretima, Radix Bupleuri, Radix Glycyrrhizae added 10 times of water gagings decoct secondaries, 2 hours for the first time, 1 hour for the second time, collecting decoction filtered, it is 1.23-1.26 that filtrate is concentrated into relative density, the clear paste when temperature is 75 ℃ is standby;
(3), Cinnabaris, Margarita water are flown or be ground into fine powder, standby;
(4), Cornu Saigae Tataricae file is ground into fine powder, standby;
(5), with artificial Calculus Bovis, Moschus porphyrize respectively, standby;
(6), with the fine powder of step (3), (4), (5) preparation and the fine powder of step (1) preparation, the clear paste of step (2) preparation, bilein and an amount of lactose mixing are granulated, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, granulation incapsulates, promptly.
7, the medicine of treatment infantile inflammation of upper respiratory tract according to claim 5 is characterized in that:
Described dosage form is that the processing step of preparation method of tablet is as follows:
(1), Rhizoma Coptidis, Bulbus Fritillariae Ussuriensis, Mirabilitum crystallina are ground into fine powder, standby;
(2), Rhizoma Belamcandae, Rhizoma Bistortae, Radix Arnebiae (Radix Lithospermi), Radix Scutellariae, Pheretima, Radix Bupleuri, Radix Glycyrrhizae added 10 times of water gagings decoct secondaries, 2 hours for the first time, 1 hour for the second time, collecting decoction filtered, it is 1.23-1.26 that filtrate is concentrated into relative density, the clear paste when temperature is 75 ℃ is standby;
(3), Cinnabaris, Margarita water are flown or be ground into fine powder, standby;
(4), Cornu Saigae Tataricae file is ground into fine powder, standby;
(5), with artificial Calculus Bovis, Moschus porphyrize respectively, standby;
(6), with the fine powder of step (3), (4), (5) preparation and the fine powder of step (1) preparation, the clear paste of step (2) preparation, bilein and an amount of lactose mixing are granulated, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, compacting is wrapped film-coat, promptly in flakes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041787 CN1682896A (en) | 2005-03-10 | 2005-03-10 | Medicine for treating infantile inflammation of upper respiratory tract and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041787 CN1682896A (en) | 2005-03-10 | 2005-03-10 | Medicine for treating infantile inflammation of upper respiratory tract and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1682896A true CN1682896A (en) | 2005-10-19 |
Family
ID=35262515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510041787 Pending CN1682896A (en) | 2005-03-10 | 2005-03-10 | Medicine for treating infantile inflammation of upper respiratory tract and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1682896A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100420456C (en) * | 2006-03-14 | 2008-09-24 | 北京国丹药物技术开发有限公司 | Compounded Radix Bupleuri enema preparation and preparing method |
| JP2011522883A (en) * | 2008-06-13 | 2011-08-04 | アングク ファーマシューティカル カンパニー リミテッド | Composition for prevention and treatment of respiratory diseases containing yellow lotus extract as an active ingredient |
| CN102058830B (en) * | 2009-11-12 | 2013-06-12 | 哈尔滨蒲公英药业有限公司 | Medicinal composition preparation and preparation method thereof |
| CN103462889A (en) * | 2013-08-09 | 2013-12-25 | 林凡友 | Ibuprofen suspension and preparation method thereof |
-
2005
- 2005-03-10 CN CN 200510041787 patent/CN1682896A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100420456C (en) * | 2006-03-14 | 2008-09-24 | 北京国丹药物技术开发有限公司 | Compounded Radix Bupleuri enema preparation and preparing method |
| JP2011522883A (en) * | 2008-06-13 | 2011-08-04 | アングク ファーマシューティカル カンパニー リミテッド | Composition for prevention and treatment of respiratory diseases containing yellow lotus extract as an active ingredient |
| US8425953B2 (en) | 2008-06-13 | 2013-04-23 | Ahn-Gook Pharmaceutical Co., Ltd. | Extract of Coptidis rhizoma and novel use thereof in treating respiratory disease |
| US8871282B2 (en) | 2008-06-13 | 2014-10-28 | Ahn-Gook Pharmaceutical Co., Ltd. | Extract of Coptidis rhizoma and novel use thereof in treating respiratory disease |
| USRE45524E1 (en) | 2008-06-13 | 2015-05-19 | Ahngook Pharmaceutical Co., Ltd. | Extract of Coptidis rhizoma and novel use thereof in treating respiratory disease |
| CN102058830B (en) * | 2009-11-12 | 2013-06-12 | 哈尔滨蒲公英药业有限公司 | Medicinal composition preparation and preparation method thereof |
| CN103462889A (en) * | 2013-08-09 | 2013-12-25 | 林凡友 | Ibuprofen suspension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN101066340A (en) | Compound externally applied tetrodotoxin ointment and its prepn | |
| CN1270746C (en) | Medicine for diminishing the inflammation and reducing the pain, subsiding swelling to dissipate indurated mass, dredging meridian to removing stagnation | |
| CN1682896A (en) | Medicine for treating infantile inflammation of upper respiratory tract and its preparing method | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1864730A (en) | A cancer-treating medicine | |
| CN101049345A (en) | A preparation for treating disease of oral cavity and gorge, and preparation method | |
| CN100337644C (en) | Chinese medicine for treating peptic ulcer and its prepn process | |
| CN1823912A (en) | Antiphlogistic medicine | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN102397533B (en) | Compound propolis composition for treating livestock egg drop syndrome and preparation method thereof | |
| CN1130217C (en) | Medicine for preventing and treating cancer and preparation process thereof | |
| CN1899387A (en) | Method for preventing and treating child convulsion and its preparing method | |
| CN1628770A (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1814116A (en) | Chinese medicine for treating gastric cavity ache and preparing method | |
| CN1660413A (en) | New aplication of interferon pastille in use for preparing medication of treating recurrent ulcer of oral cavity | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis | |
| CN1175870C (en) | Constipation treating medicine and its prepn | |
| CN1176688C (en) | Medicine for treating acute and chronic pharyngitis and its prepn | |
| CN1157218C (en) | Medicine for curing rheumatism and rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |